Related Experiment Video
Updated: Sep 19, 2025

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
Percutaneous Transcatheter Edge-to-Edge Repair for Functional Mitral Regurgitation in Heart Failure: A Systematic
Ramy Ghaly1,2, Ahmed Mazen Amin3, Samuel Kim1
1University of Missouri-Kansas City, Kansas City, Missouri, USA.
Background:
Mitral transcatheter edge-to-edge repair (TEER) is approved for patients with severe functional mitral regurgitation (FMR) beyond optimal medical therapy (OMT).
Aims:
We aimed to assess TEER's efficacy beyond OMT in patients with severe FMR.
Methods:
A systematic review and meta-analysis were conducted, including randomized controlled trials from PubMed, Cochrane, Scopus, and EMBASE up to September 2024.
Primary Outcome:
heart failure hospitalization (HFH); secondary outcomes: cardiovascular (CV) mortality, all-cause mortality, and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores. Time-to-event data from Kaplan-Meier curves were reconstructed for individual patient data.
Results:
Three studies (1423 patients) were included. TEER significantly reduced HFH (RR 0.73, 95% CI 0.58-0.92, p < 0.01) and CV mortality (RR 0.79, 95% CI 0.66-0.95, p = 0.01), and improved KCCQ scores (mean difference 14.32, 95% CI 10.85-17.80, p < 0.01) compared to OMT. No significant difference was found for all-cause mortality (RR 0.80, 95% CI 0.63-1.02, p = 0.07). Prognostic meta-analysis showed a 34% reduced risk of HFH (HR 0.66, 95% CI 0.45-0.96, p = 0.03), but no effect on all-cause or CV mortality. Reconstructed Kaplan-Meier analysis confirmed a 34% reduced risk of HFH (HR 0.65, p < 0.001), with effect attenuation after 15 months in landmark analysis (HR 0.64, p = 0.07). RMST analysis showed a 2.9-month longer HFH-free survival with TEER (p < 0.01).
Conclusion:
In patients with FMR, TEER significantly reduces HFH, improves functional status, and lowers CV mortality at 24 months but does not significantly affect all-cause mortality. The device group experienced a modest, but significant, 2.9-month longer HFH-free survival compared to the control group. However, the reduction in HFH showed attenuation beyond 15 months.
More Related Videos
Related Concept Videos
Mitral Regurgitation III: Medical Management
Mitral Stenosis III: Medical Management
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Mitral Regurgitation IV: Nursing Management
Mitral Regurgitation I: Introduction
Mitral Valve Prolapse II: Assessment and Management

